David Darling has a dig at DHB delays

David Darling has a dig at DHB delays
David Darling: Disappointed with slow adoption (Image: Supplied)
Brent Melville
Pacific Edge’s cancer diagnostic products have made headway into the US healthcare sector over the past several years, but many New Zealand patients continue to be shut out by the bureaucracy of local DHBs, the company says.Last June, the NZX-listed firm announced giant US healthcare group Kaiser Permanente had approved its Cxbladder products for use by urologists to monitor patients for bladder cancer. A month later it announced Cxbladder tests will be covered by the Centers for Medicare and Medicaid Services (CMS) across the US mar...

More Markets

Vulcan Steel leads as reporting season approaches
Markets Market Close

Vulcan Steel leads as reporting season approaches

The S&P/NZX 50 Index closed 55.30 points higher at 12,889.38.

Jamie Gray 15 Aug 2025
Small cap spotlight: Blackpearl Group
Markets Small Cap Wrap

Small cap spotlight: Blackpearl Group

Founder Nick Lissette says it's patriotic to be listed, but hard work.

Competition law changing to allow 'beneficial collaboration'
Markets

Competition law changing to allow 'beneficial collaboration'

Confidential submissions to the Commerce Commission will get a 10-year OIA exemption.

Pattrick Smellie 15 Aug 2025
NZ sharemarket rises, Vista Group shares fall
Markets Market Close

NZ sharemarket rises, Vista Group shares fall

The New Zealand sharemarket was up on Thursday as most stocks on the main board lifted.

Tom Raynel 14 Aug 2025